Statistics
Publications
14
Citations
2.7K
H-Index
13
Active since
1989
Refaat Shalaby is an author at University of California, San Francisco specializing in molecular oncology, pharmacology, and oncology.
Publications per year
1989–2002
14
14
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
John W. Park, Keelung Hong, Dmitri B. Kirpotin et al. · PubMed · 2002 · 648 citations · Full text
Pharmacy, Oncology, Pharmacology +17
Anders Waage, Alfred Halstensen, Refaat Shalaby et al. · The Journal of Experimental Medicine · 1989 · 458 citations · Full text
Tumor targeting using anti-her2 immunoliposomes
J.W. Park, Dmitri B. Kirpotin, Keelung Hong et al. · Journal of Controlled Release · 2001 · 332 citations
Medicine, Cancer Biology, Oncology +12
Development of anti-p185HER2 immunoliposomes for cancer therapy.
J W Park, Keelung Hong, Paul Carter et al. · Proceedings of the National Academy of Sciences · 1995 · 259 citations
Medicine, Oncology, Pharmacology +17
Terje Espevik, Manfred Brockhaus, Hansruedi Loetscher et al. · The Journal of Experimental Medicine · 1990 · 254 citations · Full text
1–5 of 14